Going forward, prospective studies assessing how DC‐based therapies influence the long‐term outcome of such patients will be necessary to determine whether immunologic interventions that induce tumor‐specific effector CD8+ T cell differentiation confer long‐term protection against disease recurrence. The gene discussed is CD8A; the disease is neoplasm.